European Health and Digital Executive Agency (HaDEA)’s Post

Lung cancer is challenging enough - imagine facing it without access to essential tests or treatments. For many EGFR+ patients worldwide, this is a reality. A recent study highlights not only the high prevalence of EGFR mutations but also the barriers to care in underserved regions, where diagnostics and treatment options are often out of reach. This gap impacts outcomes globally and shows why we need solutions that make lung cancer care affordable and accessible for everyone. #HealthInequity #EGFR #LungCancer OncoDaily 🙏 https://lnkd.in/eMikHgAg

In the UK, 70% of people with pancreatic cancer never receive treatment – this is the lowest proportion of all cancers. Half are diagnosed in an emergency setting. And over 50% die within 3 months of being diagnosed.   For 5-year survival rates, the UK ranks below 14 European countries with comparable, reliable data: Latvia Belgium Portugal Germany Estonia Sweden Ireland Norway Switzerland France Poland Denmark Spain Netherlands   In its Don’t Write Me Off campaign, Pancreatic Cancer UK is calling for faster diagnosis (with 21 days of being sent for tests) and faster treatment t(within 21 days of diagnosis) to improve these frankly shocking figures.    #medicalinnovation #pancreaticcancer #DontWriteMeOff #HIPEC #CombatMedical

🌍 Cancer Burden in LMICs: A Growing Crisis 📈 In 2012, 65% of all cancer deaths globally occurred in low- and middle-income countries (LMICs). This alarming figure is projected to rise to 75% by 2030. Due to the lack of reliable cancer registries and reporting systems, the true burden of cancer in LMICs might be even higher. Let's work together to improve cancer care and reporting in LMICs. Read more: https://lnkd.in/g2PfZgd5 #CancerAwareness #GlobalHealth #LMICs #HealthcareInequality

In the UK, 70% of people with pancreatic cancer never receive treatment – this is the lowest proportion of all cancers. Half are diagnosed in an emergency setting. And over 50% die within 3 months of being diagnosed.   For 5-year survival rates, the UK ranks below 14 European countries with comparable, reliable data: Latvia Belgium Portugal Germany Estonia Sweden Ireland Norway Switzerland France Poland Denmark Spain Netherlands   In its Don’t Write Me Off campaign, Pancreatic Cancer UK is calling for faster diagnosis (with 21 days of being sent for tests) and faster treatment t(within 21 days of diagnosis) to improve these frankly shocking figures.    #medicalinnovation #pancreaticcancer #DontWriteMeOff #HIPEC #CombatMedical

On #WorldCancerDay, let's stand together against the alarming rise in cancer cases in #India. ICMR data shows that India is projected to have 15.7L cases by 2025. Meanwhile, the American Cancer Society anticipates over 2M new cases in the US in 2024, with 611,000 expected deaths, while #WHO reports that in 2022, ~20M new cancer cases surfaced and 9.7M deaths occurred. This rising incidence and mortality call for collective action! Let's invest in oncology #innovations that can mend the way for advanced #treatments, early detection, and improved #patient outcomes. Your support can make a significant impact and contribute to a future where #cancer is less formidable. Together, let's make strides towards a healthier world! If you have an #oncology product that can make a significant difference, we encourage you to reach out to us at www.bioangels.vc/contact/. Let’s discuss how we can help you advance the fight against cancer.

Understanding Low Lung Cancer Screening Rates in the US A recent study by JAMA Network reveals that only 18% of eligible individuals in the US were up to date with recommended lung cancer screenings (LCS) in 2022. The findings show significant variability across states, with the lowest rates in southern states. Key Insights: - Nationwide LCS rates remain low - Socioeconomic and access disparities affect screening rates - States with Medicaid expansion and higher LCS capacity see better outcomes These insights highlight the need for better healthcare access and screening facilities. For more details, read the full article:

Rare cancers often pose unique and complex challenges, requiring specialised research, treatment, and support. It is critical to increasing survivorship that awareness is raised about these conditions. Working together is vital to improving the outlook and outcomes for those affected. Together, we aim to change these statistics by advocating for more funding, research, and resources for rare cancer patients.💛 #RareCancerAwareness #MakeADifference #CancerResearch #cquence #cquenceaustralia #rarecancer

While experts have made significant advances in treating cancer, cancer continues to remain a global health concern. The latest report from the World Health Organization predicts that there will be over 35 million new cases of cancer in 2050, a significant rise from the approximate 20 million cancer cases that occurred in 2022. Reports from the International Agency for Research on Cancer found that lung, breast, and colorectal cancers are the most common types worldwide. Learn more: https://lnkd.in/edp7t3aa Never miss an opportunity to learn and subscribe to our email list: https://lnkd.in/g3Ps94t  ————————————————————— #diversityinclinicalresearch #clinicaltrial #diversityinmedicine #diversitymatters #diversity #diversidad

🕒Timely diagnosis saves lives, especially when it comes to lung cancer. This World Patient Safety Day 2024, let’s emphasize safety and early screening for better outcomes.   SOLACE is working to enhance awareness and participation rates in lung cancer screening, particularly in underrepresented communities across Europe. The project also aims to improve the quality of lung cancer screening across Europe.   Click here to learn more https://lnkd.in/eukiSx7N   #SOLACELUNG #HealthUnion #EUCancerPlan #EU4Health #worldpatientsafetyday #WPSD24   European Health and Digital Executive Agency (HaDEA) European Commission

For those diagnosed with EGFR mutation positive NSCLC, this is a groundbreaking RCT from India. This is one of the very few randomised study done from India in lung cancer. This provides less costly alternative to our people. We require many more research like this for the Indian population. For such clinical trials to work we need participation from those who have been diagnosed with cancer. Without you such results are impossible to obtain. We encourage you to come forward and be a part of clinical trials. Please speak to your treating oncologist who will help you understand everything about such clinical trials. Please access the link shared for detailed information! Click here to know more :- https://lnkd.in/dCwAGD3R #clinicaltrials #clinicalresearch #groundbreakingnews #cancerawareness #CloseTheCareGap #cancertreatment #mentalhealthsupport #cancersupportcommunity #patientcare #mentalhealthawareness #cancerprevention #CancerAwarenessMonth #lungcancerawareness #lungcancerscreening #NSCLC #EGFR